SAN FRANCISCO, -- The launch of the Global Colon Cancer Alliance (GCCA) was announced today at the ASCO Gastrointestinal Cancers Symposium in San Francisco, California. The newly formed alliance unites two leading advocacy organizations: the Colon Cancer Alliance, a patient advocacy organization based in the United States and its European counterpart, EuropaColon. GCCA will effectively address the issues and provide information surrounding colorectal cancer to clinicians, patients and caregivers across the globe.
"We are excited to be a part of a global organization that will provide hope to a greater number of people around the world," said Andrew Spiegel, CEO of the Colon Cancer Alliance and co-founder and co-chair of GCCA. "We have made huge strides in the United States to bring greater awareness to colon cancer. Combining our efforts with the fantastic work done by EuropaColon will help us ensure that our message of getting tested for colon cancer is heard globally. Through GCCA, we now have the global ability to make a powerful impact on this preventable disease."
Jola Gore-Booth, CEO of EuropaColon and co-founder and co-chair of GCCA added, "EuropaColon's aim has been to unite people across Europe by establishing advocacy groups and creating a wide colorectal cancer advocacy community. Through the Global Colon Cancer Alliance, we can now unite people from around the world, working towards the same goals. It is an honor for us to partner with the Colon Cancer Alliance, the oldest colorectal cancer patient organization in the United States.
The first study, to be published in the February issue of Gastroenterology, shows that a new multi-marker stool DNA test is highly accurate at detecting precancerous polyps and early-stage colorectal cancer. This is the first large-scale, blinded study to measure the new test’s effectiveness.
The second study, to be published in the March issue of Clinical Gastroenterology and Hepatology, shows that the stool DNA test is significantly more accurate than a new plasma test for identifying patients with large precancerous polyps or colorectal cancer, while delivering fewer false-positive results.
“Our findings in these studies underscore the great potential of the stool DNA test as a colorectal cancer screening tool,” says lead author David Ahlquist, M.D., of Mayo Clinic, principal investigator of both studies. “Along with its high accuracy, this test approach could improve participation rates due to its patient-friendly features. The test is noninvasive; requires no bowel preparation, medication restriction, or diet change; and can be performed on mailed-in samples without the need, expense, or inconvenience of a health care visit.”
The stool DNA test works by finding signature genetic markers in stool samples mailed in by patients. A positive test would be followed by a colonoscopy to remove the polyps and prevent a subsequent cancer from forming, Dr. Ahlquist says.
First Study Highlights Stool DNA Test’s Accuracy
Titled “Next-Generation Stool DNA Testing for Detection of Colorectal Neoplasia: Early Clinical Evaluation,” the first article features results from the first large-scale study to measure the test’s accuracy:
Across nearly 400 cases, the stool DNA test detected 87 percent of curable-stage colorectal cancer. Importantly, detection sensitivity was not affected by tumor location or stage.
The test detected the majority of large precancerous polyps at high risk for cancer progression.
Sensitivity was 64 percent for polyps larger than 1 centimeter (cm), 77 percent for those larger than 2 cm and 92 percent for those larger than 4 cm.
“These data illustrate the strength of the multi-marker stool DNA test to the critical screening targets — pre-cancers and early-stage cancer,” says co-investigator Stephen Thibodeau, Ph.D., a genetics researcher at Mayo Clinic. “And, importantly, this test appears to uniquely represent an accurate noninvasive approach to large polyp detection, which offers the promise of actually preventing cancers from developing.”
The second article, titled “Stool DNA vs. Plasma Septin 9 Testing,” uses the results of the first study to compare the sensitivities of the stool DNA test and a plasma test for methylated Septin 9 (SEPT9) in identifying patients with large adenomas or colorectal cancer. Highlights include:
The stool DNA test detected 82 percent of precancerous polyps compared to only 14 percent detected by SEPT9.
The stool DNA identified 87 percent of cancers at any stage, compared to 60 percent with SEPT9.
Stool DNA was even more effective at detecting curable-stage cancer (Stage I, II or III), detecting such cases 91 percent of the time, compared to just 50 percent with SEPT9.
The SEPT9’s rate of false-positives was nearly four times that of stool DNA (27 percent vs. 7 percent).
"We are excited to be a part of a global organization that will provide hope to a greater number of people around the world," said Andrew Spiegel, CEO of the Colon Cancer Alliance and co-founder and co-chair of GCCA. "We have made huge strides in the United States to bring greater awareness to colon cancer. Combining our efforts with the fantastic work done by EuropaColon will help us ensure that our message of getting tested for colon cancer is heard globally. Through GCCA, we now have the global ability to make a powerful impact on this preventable disease."
Jola Gore-Booth, CEO of EuropaColon and co-founder and co-chair of GCCA added, "EuropaColon's aim has been to unite people across Europe by establishing advocacy groups and creating a wide colorectal cancer advocacy community. Through the Global Colon Cancer Alliance, we can now unite people from around the world, working towards the same goals. It is an honor for us to partner with the Colon Cancer Alliance, the oldest colorectal cancer patient organization in the United States.
The first study, to be published in the February issue of Gastroenterology, shows that a new multi-marker stool DNA test is highly accurate at detecting precancerous polyps and early-stage colorectal cancer. This is the first large-scale, blinded study to measure the new test’s effectiveness.
The second study, to be published in the March issue of Clinical Gastroenterology and Hepatology, shows that the stool DNA test is significantly more accurate than a new plasma test for identifying patients with large precancerous polyps or colorectal cancer, while delivering fewer false-positive results.
“Our findings in these studies underscore the great potential of the stool DNA test as a colorectal cancer screening tool,” says lead author David Ahlquist, M.D., of Mayo Clinic, principal investigator of both studies. “Along with its high accuracy, this test approach could improve participation rates due to its patient-friendly features. The test is noninvasive; requires no bowel preparation, medication restriction, or diet change; and can be performed on mailed-in samples without the need, expense, or inconvenience of a health care visit.”
The stool DNA test works by finding signature genetic markers in stool samples mailed in by patients. A positive test would be followed by a colonoscopy to remove the polyps and prevent a subsequent cancer from forming, Dr. Ahlquist says.
First Study Highlights Stool DNA Test’s Accuracy
Titled “Next-Generation Stool DNA Testing for Detection of Colorectal Neoplasia: Early Clinical Evaluation,” the first article features results from the first large-scale study to measure the test’s accuracy:
Across nearly 400 cases, the stool DNA test detected 87 percent of curable-stage colorectal cancer. Importantly, detection sensitivity was not affected by tumor location or stage.
The test detected the majority of large precancerous polyps at high risk for cancer progression.
Sensitivity was 64 percent for polyps larger than 1 centimeter (cm), 77 percent for those larger than 2 cm and 92 percent for those larger than 4 cm.
“These data illustrate the strength of the multi-marker stool DNA test to the critical screening targets — pre-cancers and early-stage cancer,” says co-investigator Stephen Thibodeau, Ph.D., a genetics researcher at Mayo Clinic. “And, importantly, this test appears to uniquely represent an accurate noninvasive approach to large polyp detection, which offers the promise of actually preventing cancers from developing.”
The second article, titled “Stool DNA vs. Plasma Septin 9 Testing,” uses the results of the first study to compare the sensitivities of the stool DNA test and a plasma test for methylated Septin 9 (SEPT9) in identifying patients with large adenomas or colorectal cancer. Highlights include:
The stool DNA test detected 82 percent of precancerous polyps compared to only 14 percent detected by SEPT9.
The stool DNA identified 87 percent of cancers at any stage, compared to 60 percent with SEPT9.
Stool DNA was even more effective at detecting curable-stage cancer (Stage I, II or III), detecting such cases 91 percent of the time, compared to just 50 percent with SEPT9.
The SEPT9’s rate of false-positives was nearly four times that of stool DNA (27 percent vs. 7 percent).
No comments:
Post a Comment